Company: SMNR
Filing Date: 2025-04-21
Form Type: CORRESP
Source: 0001193125-25-087365
Chunk: 15

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-04-21
Form: CORRESP
Chunk 15
---
 similar revisions to your sales and marketing disclosure on page 275 as appropriate.                                                                       |

Response: The Company respectfully advises the Staff that it has revised the disclosure on pages 290, 301 and 324 of Amendment No. 1 in response to the Staff’s comment. Our Solution, page 267

| 32. | We note your statement in the first full paragraph on page 268 regarding your expected commercial launch                                                                       
 of SP-102 in 2027. Please revise your disclosure to clarify that there is no guarantee that you will be able to commence a commercial launch of SP-102 in 2027 or ever,        
 as any such launch would be subject to regulatory approval, which you may not receive. Please make similar revisions throughout the proxy statement/prospectus as appropriate. |

13

U.S. Securities and Exchange Commission April 21, 2025 Response: The Company respectfully advises the Staff that it has revised the disclosure on pages 76, 194 and 292 of Amendment No. 1 in response to the Staff’s comment. Material Agreements Shah Assignment Agreement, page 279

| 33. | Please disclose whether your Chief Executive Officer, Jaisim Shah, has any direct or indirect material                                                                                                     
 interest in the Shah Assignment Agreement and, to the extent applicable, provide the information required by Item 404 of Regulation S-K in the section of the proxy statement/prospectus regarding certain 
 relationships and related party transactions. Refer to Item 18(a)(7)(iii) of Form S-4.                                                                                                                     |

Response: The Company respectfully advises the Staff that it has revised the disclosure on page 306 of Amendment No. 1 in response to the Staff’s comment to reflect that Semnur’s Chief Executive Officer, Jaisim Shah, is not related to the Shah Investor and that he has no direct or indirect material interest in Shah Assignment Agreement. Intellectual Property, page 280

| 34. | We note your disclosure that, with respect to SP-102, your                                                                                                                                                        
 patents and patent applications include formulations and methods of treatment. Please clarify whether you own or in-license these patents and patent applications. For example, clarify whether these patents and 
 patent applications are the subject(s) of the Shah Assignment Agreement.                                                                                                                                          |

Response: The Company acknowledges the Staff’s comment and respectfully advises the Staff that Semnur owns these patents and patent applications, pursuant to an Assignment Agreement Semnur entered into with Mahendra G. Shah, the inventor, dated as of